Table 2.

Patients with reproductive problems and irregular menstruation or amenorrhea as delayed effects

Healthy AYA age groups	Respondents with infertility or problems with reproductive function No. (%)
15‐39 y (n = 100)	3 (3.0)—(a)
30‐39 y (n = 25)	3 (12.0)—(b)

	AYA survivors who underwent chemotherapy
	Number of respondents with infertility or problems with reproductive function	Irregular menstruation or amenorrhea as late effect
All, n = 115	48 (41.4%) vs (b) P < 0.01	42 (36.2%)
Excluding breast cancer, n = 92	32 (34.8%) vs (b) P < 0.05	35 (38.0%)
Breast cancer, n = 23	16 (69.6%) vs (b) P < 0.01	7 (30.4%) (excludes eight survivors with amenorrhea induced by hormone therapy)
Hematologic malignancy, n = 55	19 (34.5%) vs (b) 0.05 < P<0.10, vs (a) P < 0.01	23 (41.8%)
Excluding breast cancer and hematologic malignancy, n = 37	13 (35.1%) vs (b) 0.05 < P<0.10, vs (a) P < 0.01	12 (32.4%)
AYA at primary diagnosis, n = 52	27 (51.9%) vs (b) P < 0.01, vs (a) P < 0.01	19 (36.5%)

AYA, adolescent and young adults.